TY - JOUR AU - Heck, Matthias M. AU - Gschwend, Jürgen E. AU - Retz, Margitta PY - 2012 TI - Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients JF - Translational Andrology and Urology; Vol 2, No 2 (June 16, 2013): Translational Andrology and Urology Y2 - 2012 KW - N2 - Until lately, castration-resistant prostate cancer (CRPC) patients who progressed following docetaxel chemotherapy had no treatment alternative with proven survival benefit. This changed with a series of recently published phase III trials that lead to approval of several new, life-prolonging agents by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). UR - https://tau.amegroups.org/article/view/1206